- Home
- RLYB vs BOLT Comparison
RLYB vs BOLT Comparison
Compare RLYB & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- BOLT
- Stock Information
- Founded
- RLYB 2018
- BOLT 2015
- Country
- RLYB United States
- BOLT United States
- Employees
- RLYB N/A
- BOLT N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- BOLT Health Care
- Exchange
- RLYB Nasdaq
- BOLT Nasdaq
- Market Cap
- RLYB 13.3M
- BOLT 16.8M
- IPO Year
- RLYB 2021
- BOLT 2021
- Fundamental
- Price
- RLYB $0.29
- BOLT $0.37
- Analyst Decision
- RLYB Hold
- BOLT Hold
- Analyst Count
- RLYB 4
- BOLT 5
- Target Price
- RLYB $15.00
- BOLT $1.13
- AVG Volume (30 Days)
- RLYB 93.6K
- BOLT 106.7K
- Earning Date
- RLYB 05-08-2025
- BOLT 05-13-2025
- Dividend Yield
- RLYB N/A
- BOLT N/A
- EPS Growth
- RLYB N/A
- BOLT N/A
- EPS
- RLYB N/A
- BOLT N/A
- Revenue
- RLYB $848,000.00
- BOLT $7,690,000.00
- Revenue This Year
- RLYB N/A
- BOLT N/A
- Revenue Next Year
- RLYB N/A
- BOLT $77.48
- P/E Ratio
- RLYB N/A
- BOLT N/A
- Revenue Growth
- RLYB N/A
- BOLT N/A
- 52 Week Low
- RLYB $0.22
- BOLT $0.30
- 52 Week High
- RLYB $2.00
- BOLT $1.34
- Technical
- Relative Strength Index (RSI)
- RLYB 35.98
- BOLT 50.57
- Support Level
- RLYB $0.29
- BOLT $0.33
- Resistance Level
- RLYB $0.33
- BOLT $0.38
- Average True Range (ATR)
- RLYB 0.02
- BOLT 0.03
- MACD
- RLYB 0.02
- BOLT 0.00
- Stochastic Oscillator
- RLYB 56.47
- BOLT 50.00
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.